ALXN : Summary for Alexion Pharmaceuticals, Inc. - Yahoo Finance

U.S. Markets closed

Alexion Pharmaceuticals, Inc. (ALXN)


NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
128.82-1.57 (-1.20%)
At close: 4:00PM EST
People also watch
REGNBMRNVRTXBIIBCELG
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close130.39
Open130.00
Bid111.96 x 100
Ask128.97 x 100
Day's Range125.20 - 130.23
52 Week Range109.12 - 162.00
Volume2,721,950
Avg. Volume2,801,001
Market Cap28.85B
Beta1.39
PE Ratio (TTM)78.55
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Alexion Pharmaceuticals, Inc. (ALXN) Suffers Another Blow In The UK
    Insider Monkey2 days ago

    Alexion Pharmaceuticals, Inc. (ALXN) Suffers Another Blow In The UK

    Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) has had another misfortune in the UK. The country’s public health watchdog, NICE (the National Institute for Health and Care Excellence) declined to recommend Alexion’s Kanuma as a treatment for an ultra-rare disease called lysosomal acid lipase deficiency (LAL). The refusal by NICE to recommend Kanuma comes shortly after the same […]

  • Alexion Pharmaceuticals, Inc. :ALXN-US: Earnings Analysis: Q4, 2016 By the Numbers : February 17, 2017
    Capital Cube2 days ago

    Alexion Pharmaceuticals, Inc. :ALXN-US: Earnings Analysis: Q4, 2016 By the Numbers : February 17, 2017

    Categories: Yahoo Finance Get free summary analysis Alexion Pharmaceuticals, Inc. reports financial results for the quarter ended December 31, 2016. We analyze the earnings along side the following peers of Alexion Pharmaceuticals, Inc. – Celgene Corporation, Regeneron Pharmaceuticals, Inc., Gilead Sciences, Inc., Vertex Pharmaceuticals Incorporated, Biogen Inc., QIAGEN NV and Ultragenyx Pharmaceutical, Inc. (CELG-US, REGN-US, GILD-US, VRTX-US, BIIB-US, ... Read more (Read more...)

  • Barrons.com2 days ago

    [$$] Takeover Candidate Alexion Is on the Mend

    Is Alexion Pharmaceuticals on the comeback trail? Since mid-2015, when Alexion (ALXN) traded above $200, shares have tumbled more than 35% on worries about the durability of its main drug Soliris, political furor over high drug prices, and the abrupt departure of its two top executives amid an investigation into sales practices. On Thursday, Alexion announced mixed fourth-quarter results, a full-year revenue forecast that was better than many expected and a $1 billion stock buyback.